November 2021 Top Biopharma Deal: Sanofi – Owkin artificial intelligence and federated learning platform to advance Sanofi’s oncology pipeline

by | Dec 8, 2021

November 2021 Top Biopharma Deal Upfront

Owkin discovery and development deal with Sanofi for AI models for cancer

Announced: November 18, 2021

Total Deal Value: $270M + Mst

Upfront Cash: none

Upfront Equity: $180M

R&D Funding: $90M over 3 years

Milestones: undisclosed R&D Mst

Royalty: n/a

Cost and Profit Split: n/a

The Asset:

Owkin’s artificial intelligence and federated learning platform to support digital clinical research in Sanofi’s core oncology efforts in 4 different cancers.

Deal Structure:

R&D Only

Partnership Features:

Collaborative Development, Funded R&D

The Details:

  • Owkin will receive a $180M upfront equity investment, $90M in R&D funding over 3 years, and is eligible for additional undisclosed R&D milestones.
  • Sanofi will apply Owkin’s artificial intelligence (AI) and federated learning platform to advance its oncology pipeline, which includes non-small cell lung cancer (NSCLC), triple-negative breast cancer, mesothelioma, and multiple myeloma. This research partnership agreement will allow Sanofi to work closely with Owkin to identify new oncology treatments across 4 cancers.
  • Sanofi will use the Owkin platform to find new biomarkers and therapeutic targets, build prognostic models, and predict response to treatment from multimodal patient data.
  • Owkin’s global research network is powered by federated learning, which allows data scientists to securely connect to decentralized, multi-party data sets to train AI models without having to pool data. This approach will complement Sanofi’s developments oncology.

Last Month:

Congrats to Owkin and Sanofi for landing DealForma’s November 2021 Top Biopharma Deal. Last month’s Deal of the Month was Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

Want data for your analysis? Want us to do it? Subscribers get both.

Schedule your demo of the DealForma database to see how we help you get better reports done faster.

25,544

Deal Profiles

15,147

Funding Rounds

28,034

Company Profiles

17,936

Product Profiles

119K+

Clinical Trials

3,982

Business Developers

Specifically for Biotech, Pharma, Device, and Diagnostics

Get more done.

Stop cleaning data or getting lost in legacy databases. We built DealForma to help you be better and faster at business research. Schedule your customized demo to see how DealForma helps you impress your boss and sign-off early.

More Research by DealForma

January 2022 Top Biopharma Deal: Beam – Pfizer In Vivo Base Editing and Delivery Programs for Rare Diseases

January 2022 Top Biopharma Deal: Beam – Pfizer In Vivo Base Editing and Delivery Programs for Rare Diseases

The top deal upfront for January 2022 was the Beam Therapeutics research partnership with Pfizer with an option to license in vivo base editing programs. Beam will receive $300M up front, up to up to $1.05B in development, regulatory, and sales milestones, plus royalties per licensed program. If Beam opts in to co-develop/co-promote a program, the companies will share cost and profits 65%/35% (Pfizer/Beam).

read more
October 2021 Top Biopharma Deal: Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies

October 2021 Top Biopharma Deal: Xencor – Janssen for Plamotamab and XmAb Bispecific Antibodies

The top deal upfront for October 2021 was the Xencor – Janssen deal for plamotamab and XmAb bispecific antibodies and new XmAb B-cell targeting bispecific antibodies for CD20-expressing hematologic malignancies. Xencor will receive $100M in upfront cash, $25M in an upfront equity investment, and is eligible for up to $1.18B in dev., reg., and sales milestones, plus tiered mid-teens to low-twenties royalties.

read more
September 2021 Top Biopharma Deal: REGENXBIO – AbbVie for RBX-314 for wet AMD, diabetic retinopathy

September 2021 Top Biopharma Deal: REGENXBIO – AbbVie for RBX-314 for wet AMD, diabetic retinopathy

The top deal upfront for September 2021 was the REGENXBIO – AbbVie deal for RGX-314 for wet AMD, diabetic retinopathy, and other chronic retinal diseases. REGENXBIO will receive $370M up front and is eligible for up to $1.38B in milestones, plus tiered royalties on net sales of RGX-314 outside the US and 50% of profits in the US.

read more
Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

CRISPR Therapeutics and Vertex Pharmaceuticals amended their 2015 deal to develop and commercialize gene editing therapies. This expansion is for Phase I/II CTX001 for severe sickle cell diseases and transfusion-dependent beta-thalassemia. CRISPR will receive $900M up front, up to $200M in milestones upon the first regulatory approval, and a cost/profit split of 40%.

read more
Top Biopharma Deal March 2021: Debiopharm – Merck KGaA for Xevinapant for head and neck cancer

Top Biopharma Deal March 2021: Debiopharm – Merck KGaA for Xevinapant for head and neck cancer

Debiopharm granted Merck exclusive, worldwide rights to develop and commercialize Xevinapant in Phase III for advanced squamous cell carcinoma of the head and neck. Debiopharm will receive EUR188M ($227M) up front and is eligible for up to EUR710M ($856M) in milestones, plus royalties. This was the largest upfront cash and equity for a partnership signed in March 2021.

read more

You met on Zoom. Now it's Deal Time.

With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.